vs
HomeTrust Bancshares, Inc.（HTB）とMESA LABORATORIES INC（MLAB）の財務データ比較。上の社名をクリックして会社を切り替えられます
MESA LABORATORIES INCの直近四半期売上が大きい（$65.1M vs $53.6M、HomeTrust Bancshares, Inc.の約1.2倍）。HomeTrust Bancshares, Inc.の前年同期比売上増加率が高い（3.7% vs 3.6%）。HomeTrust Bancshares, Inc.の直近四半期フリーキャッシュフローが多い（$45.3M vs $18.0M）。過去8四半期でMESA LABORATORIES INCの売上複合成長率が高い（5.1% vs 3.5%）
HomeTrust Bancshares, Inc.は米国ノースカロライナ州アッシュビルに本拠を置く銀行持株会社で、総資産は43億ドル、ノースカロライナ、サウスカロライナ、ジョージア、テネシー各州に計33店舗を展開し、HomeTrust銀行、Tryon連邦銀行など7つの地域銀行を傘下に収めています。
メサラボラトリーズ社は、品質管理、校正、モニタリング向け専門機器及び関連サービスの開発・製造・販売を事業としています。医療、製薬、食品飲料、産業衛生、環境試験分野を中心に、世界中の顧客の規制遵守と運用安全のニーズに応えています。
HTB vs MLAB — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $53.6M | $65.1M |
| 純利益 | — | $3.6M |
| 粗利率 | — | 64.2% |
| 営業利益率 | 37.0% | 12.2% |
| 純利益率 | — | 5.6% |
| 売上前年比 | 3.7% | 3.6% |
| 純利益前年比 | — | 316.6% |
| EPS（希薄化後） | $0.93 | $0.65 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $53.6M | $65.1M | ||
| Q3 25 | $54.1M | $60.7M | ||
| Q2 25 | $54.4M | $59.5M | ||
| Q1 25 | $50.9M | $62.1M | ||
| Q4 24 | $51.7M | $62.8M | ||
| Q3 24 | $50.6M | $57.8M | ||
| Q2 24 | $50.6M | $58.2M | ||
| Q1 24 | $50.0M | $58.9M |
| Q4 25 | — | $3.6M | ||
| Q3 25 | $16.5M | $2.5M | ||
| Q2 25 | $17.2M | $4.7M | ||
| Q1 25 | $14.5M | $-7.1M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | $13.1M | $3.4M | ||
| Q2 24 | $12.4M | $3.4M | ||
| Q1 24 | $15.1M | $-254.6M |
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% | ||
| Q1 24 | — | 62.1% |
| Q4 25 | 37.0% | 12.2% | ||
| Q3 25 | 38.5% | 7.8% | ||
| Q2 25 | 40.1% | 5.1% | ||
| Q1 25 | 36.2% | 2.4% | ||
| Q4 24 | 35.4% | 9.2% | ||
| Q3 24 | 33.2% | 6.1% | ||
| Q2 24 | 31.3% | 9.6% | ||
| Q1 24 | 38.0% | -460.6% |
| Q4 25 | — | 5.6% | ||
| Q3 25 | 30.5% | 4.1% | ||
| Q2 25 | 31.6% | 8.0% | ||
| Q1 25 | 28.5% | -11.4% | ||
| Q4 24 | — | -2.7% | ||
| Q3 24 | 25.9% | 5.9% | ||
| Q2 24 | 24.6% | 5.8% | ||
| Q1 24 | 30.1% | -432.2% |
| Q4 25 | $0.93 | $0.65 | ||
| Q3 25 | $0.95 | $0.45 | ||
| Q2 25 | $1.00 | $0.85 | ||
| Q1 25 | $0.84 | $-1.30 | ||
| Q4 24 | $0.83 | $-0.31 | ||
| Q3 24 | $0.76 | $0.63 | ||
| Q2 24 | $0.73 | $0.62 | ||
| Q1 24 | $0.88 | $-47.26 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $324.7M | $29.0M |
| 総負債低いほど良い | — | $68.4M |
| 株主資本純資産 | $600.7M | $186.7M |
| 総資産 | $4.5B | $434.8M |
| 負債/資本比率低いほどレバレッジが低い | — | 0.37× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $324.7M | $29.0M | ||
| Q3 25 | $315.8M | $20.4M | ||
| Q2 25 | $297.2M | $21.3M | ||
| Q1 25 | $299.8M | $27.3M | ||
| Q4 24 | $279.2M | $27.3M | ||
| Q3 24 | $293.5M | $24.3M | ||
| Q2 24 | $294.2M | $28.5M | ||
| Q1 24 | $380.5M | $28.2M |
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
| Q4 25 | $600.7M | $186.7M | ||
| Q3 25 | $595.8M | $178.5M | ||
| Q2 25 | $579.3M | $172.5M | ||
| Q1 25 | $565.4M | $159.8M | ||
| Q4 24 | $551.8M | $155.2M | ||
| Q3 24 | $540.0M | $161.5M | ||
| Q2 24 | $523.6M | $150.7M | ||
| Q1 24 | $513.2M | $145.4M |
| Q4 25 | $4.5B | $434.8M | ||
| Q3 25 | $4.6B | $430.4M | ||
| Q2 25 | $4.6B | $435.7M | ||
| Q1 25 | $4.6B | $433.3M | ||
| Q4 24 | $4.6B | $433.3M | ||
| Q3 24 | $4.6B | $454.1M | ||
| Q2 24 | $4.7B | $440.4M | ||
| Q1 24 | $4.7B | $446.8M |
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $49.5M | $18.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $45.3M | $18.0M |
| FCFマージンFCF / 売上 | 84.5% | 27.7% |
| 設備投資強度設備投資 / 売上 | 7.8% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | — | 5.17× |
| 直近12ヶ月FCF直近4四半期 | $93.8M | $37.9M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $49.5M | $18.8M | ||
| Q3 25 | $-11.3M | $8.2M | ||
| Q2 25 | $-8.8M | $1.9M | ||
| Q1 25 | $71.7M | $12.7M | ||
| Q4 24 | $45.4M | $18.1M | ||
| Q3 24 | $43.8M | $5.3M | ||
| Q2 24 | $5.9M | $10.7M | ||
| Q1 24 | $-9.0M | $12.9M |
| Q4 25 | $45.3M | $18.0M | ||
| Q3 25 | $-12.0M | $7.1M | ||
| Q2 25 | $-10.2M | $884.0K | ||
| Q1 25 | $70.7M | $11.9M | ||
| Q4 24 | $42.4M | $17.3M | ||
| Q3 24 | $43.1M | $3.5M | ||
| Q2 24 | $5.7M | $9.9M | ||
| Q1 24 | $-9.6M | $12.3M |
| Q4 25 | 84.5% | 27.7% | ||
| Q3 25 | -22.2% | 11.7% | ||
| Q2 25 | -18.7% | 1.5% | ||
| Q1 25 | 138.7% | 19.2% | ||
| Q4 24 | 82.0% | 27.6% | ||
| Q3 24 | 85.1% | 6.0% | ||
| Q2 24 | 11.2% | 16.9% | ||
| Q1 24 | -19.2% | 21.0% |
| Q4 25 | 7.8% | 1.1% | ||
| Q3 25 | 1.4% | 1.8% | ||
| Q2 25 | 2.5% | 1.7% | ||
| Q1 25 | 2.0% | 1.2% | ||
| Q4 24 | 5.9% | 1.3% | ||
| Q3 24 | 1.3% | 3.1% | ||
| Q2 24 | 0.5% | 1.5% | ||
| Q1 24 | 1.1% | 0.9% |
| Q4 25 | — | 5.17× | ||
| Q3 25 | -0.68× | 3.32× | ||
| Q2 25 | -0.51× | 0.40× | ||
| Q1 25 | 4.93× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.34× | 1.54× | ||
| Q2 24 | 0.48× | 3.17× | ||
| Q1 24 | -0.60× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
HTB
セグメントデータなし
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
